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ORIGINAL ARTICLE

Is chest tube insertion with ultrasound guidance safe in patients
using clopidogrel?
WISSAM ABOUZGHEIB,1 YOUSEF R. SHWEIHAT,2 NIKHIL MEENA2 AND THADDEUS BARTTER2
1

Cooper University Hospital, Camden, New Jersey, and 2University of Arkansas for Medical Sciences and the
Central Arkansas Veterans Hospital System, Little Rock, Arkansas, USA

ABSTRACT

SUMMARY AT A GLANCE

Background and objective: Drainage of the pleural
space is a common procedure. The safety of chest tube
insertion in patients using clopidogrel has not been
investigated.
Methods: Ultrasound-guided chest tube insertions
performed on 24 patients who were being actively
treated with clopidogrel were retrospectively reviewed.
Results: No excessive bleeding occurred in any of
these patients.
Conclusions: Given the known effects of clopidogrel
on platelet function, these results were interpreted as
indicating that clopidogrel therapy is a relative but not
an absolute contraindication to chest tube insertion,
if an experienced operator places a small-bore tube
under ultrasound guidance.

Withholding clopidogrel for 5–7 days in patients
requiring chest tube insertion for clinically significant pleural problems may be impractical. This
study has shown that in experienced hands, insertion of small-bore chest tubes under ultrasound
guidance is safe in this group of patients.

Key words: clopidogrel, pleural effusion, small-bore
chest tube, ultrasound guidance.

INTRODUCTION
Pleural effusion is a common finding; in the United
States, approximately 1 million pleural effusions are
diagnosed every year. The causes of pleural effusion
range from benign to malignant to infectious. The
investigation and treatment of pleural effusions
involve sampling or drainage of the pleural fluid by
placing a needle or catheter into the pleural cavity.
Antiplatelet therapy is a common intervention for
patients who have had stents inserted, as well as those
with other cardiovascular diseases.1–3 Clopidogrel
therapy clearly increases the risk of bleeding during
some surgical procedures, but the question of
whether it increases the risk of bleeding during chest
tube insertion has not been addressed. Currently, the
insertion of a small-bore chest tube with ultrasound
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guidance is the standard of care for treatment of most
pleural effusions, and this procedure is associated
with a very low complication rate.
We retrospectively evaluated our clinical experience with ultrasound-guided small-bore chest tube
drainage of pleural effusions in patients who were
receiving clopidogrel therapy at the time of the procedure. The primary question was whether or not the
risk of bleeding was great enough to alter clinical
practice.

METHODS
The study was approved by the Institutional Review
Board at each of the two institutions (University of
Arkansas for Medical Sciences and Sparks Health
System). A retrospective review of the medical records
identified patients who had undergone chest tube
drainage of the pleural space at either institution
between 2009 and 2011. This list was further refined to
include patients who were taking clopidogrel at the
time of chest tube insertion; these patients comprised
the study group. All procedures were performed with
ultrasound guidance and under the direct supervision
of one of two interventional pulmonologists (W.A. or
T.B.).
Our standard procedure included investigating the
chest by ultrasound examination, identifying the effusion, the diaphragm and a position in the lateral
chest, if lateral access was possible. A position anterior to the point at which the ribs angle anteriorly and
anterior to the latissimus dorsi muscle was chosen.
Doppler studies of the intercostal arteries were not
Respirology (2012) 17, 1222–1224
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performed. The site was then marked, prepared and
draped, and a pigtail catheter was inserted. Ultrasound guidance was used prior to but not during
insertion of the catheter.
The monitored parameters, when documented,
were age, gender, suspected diagnosis, pre- and postprocedure haemoglobin concentrations, the need for
transfusion, and final diagnosis. Major clopidogrelrelated complications were predefined as a reduction
in haemoglobin concentration of >20 g/L, any reduction requiring transfusion, bleeding necessitating
admission to the intensive care unit or the need for
another procedure in order to stop the bleeding.
Minor complications were predefined as a reduction
in haemoglobin concentration of >10 but <20 g/L
within 24 h of chest tube insertion and/or local bleeding (oozing) lasting more than 10 min. Other recorded
complications, if documented, included pain, local
infections and the development of empyema. The
study design included a group of control patients who
were not taking clopidogrel, but given the results of
the study, this comparison did not add value to the
findings.

RESULTS
A review of the medical records identified a total of 18
patients who underwent 24 ultrasound-guided chest
tube insertions while receiving clopidogrel therapy.
Chest tubes were inserted for drainage of pleural fluid
in 22 patients and for pneumothorax in two patients.
One patient required three separate insertions, and
two other patients required two drainage procedures
each (one for reaccumulation of fluid and the other
due to dislodgement of the tube). Thirteen of the 18
patients were taking aspirin at differing doses in addition to clopidogrel. The average age of the patients
was 73.1 years, and there were 8 men and 10 women.
The most common indications for the procedure were
pending or active respiratory failure (11/24) and
rapidly worsening dyspnoea, which were both intolerable to the patient and thought to be directly related
to a problem in the pleural space (10/24). One patient
had a large pneumothorax that necessitated drainage
twice due to dislodgement of the tube less than 1 day
after successful insertion and continued collapse of
the lung with an air leak.
Nine procedures were performed with number 8
French chest tubes, one with a number 10 tube, three
with number 12 tubes, one with a number 14 tube and
10 with number 16 tubes. The pleural fluid volume
was recorded for 21 of the 22 procedures for pleural
effusions and averaged 1.02 L per procedure. There
was one malignant effusion and two parapneumonic
effusions, while the remaining effusions were thought
to be secondary to congestive heart failure. The
patients’ average haemoglobin concentration was
100 g/L prior to the procedure and 102 g/L after the
procedure. No primary or secondary complication
was documented for any of the patients. One patient
who had a chest tube inserted for pneumothorax had
a prolonged air leak that was suggestive of a bronchopleural fistula.
© 2012 The Authors
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DISCUSSION
Thoracentesis and chest tube insertion are common
procedures for diagnostic and therapeutic indications. Patients in whom pleural drainage is withheld
while the antiplatelet effect of clopidogrel dissipates
(5–7 days) may experience a prolongation of their
hospital stay and delays in diagnosis and treatment.
In some situations, delays in pleural drainage may
lead to a preventable decompensation such as intensive care unit admission or the need for initiation of
mechanical ventilation. The results of this retrospective study suggest that it is safe, when indicated, for an
experienced operator using ultrasound guidance to
insert small-bore chest tubes in patients being treated
with clopidogrel.
The emergence of drugs that impede adenosine
diphosphate-mediated platelet aggregation, such as
clopidogrel, has led to meaningful decreases in stent
occlusion and cardiovascular events in patients with
atherosclerosis.1,4 Clopidogrel therapy results in an
increased bleeding risk that is intermediate between
the risk for aspirin and that for full anticoagulation. Investigators from different disciplines have
attempted to assess the risk of bleeding associated
with clopidogrel therapy.5–8 An interesting study by
Kwak et al.9 demonstrated that different patients have
different sensitivities to clopidogrel and that the risk
of bleeding is directly proportional to the efficacy of
the drug. The implication is that the risk of bleeding
may depend on the genetic make-up of the population being studied.
A sentinel study by Ernst et al. alerted the pulmonary community to the risks of bleeding due to use of
clopidogrel.10 That study was stopped early when a
definite increase in the risk of bleeding was noted
during transbronchial lung biopsies on patients
taking clopidogrel. Moderate or severe bleeding
occurred in 61% of patients taking clopidogrel alone,
in 100% of patients taking clopidogrel plus aspirin
and in 1.8% of patients taking neither of these drugs.
The P-values for the most important findings were
<0.001 despite the early termination of the study.
Whether these findings are applicable to other procedures has not been established; the present study suggests that the risk associated with pleural drainage is
less than that associated with transbronchial biopsy.
There are three factors that may be relevant to the
lack of complications in the patients who were
studied. The factor that may be the least well appreciated is the anatomy of the intercostal arteries, the
vessels most likely to be the source of excessive bleeding during chest tube insertion. In children, the intercostal arteries are usually concealed behind the lower
ribs and are not directly accessible to extrathoracic
puncture; however, with advancing age, the arteries
may sag below the lower rib borders and may even
become tortuous (see Fig. 1). This tendency decreases
with increasing distance from the spinal column, and
the artery is usually protected, even in older individuals, at the point where the ribs angle forward.11 Our
practice is to perform all chest tube insertions (and
thoracenteses) laterally at or anterior to the posterior
axillary line, unless loculations necessitate a posterior
Respirology (2012) 17, 1222–1224
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When the present results are assessed in the context
of the previous literature, it is our opinion that any
intervention that carries an increased risk warrants
increased caution; the potential rewards need to
justify the increased risk. This negative study should
not be regarded as proof that excessive bleeding
cannot occur when patients who are taking clopidogrel undergo chest tube insertion. It is assumed
that bleeding will occasionally occur whether or not
patients are taking clopidogrel and that the use of
clopidogrel will increase the severity of that bleeding.
In conclusion, clopidogrel therapy can be regarded
as a relative, rather than an absolute, contraindication
to chest tube insertion. If there is no urgency, clopidogrel should be withheld for at least 5 days. If a
patient who is taking clopidogrel requires immediate
chest tube insertion, then (i) the tube should be
inserted by an experienced operator, (ii) ultrasound
guidance should be used and (iii) the tube should be
inserted into the lateral chest wall when this is
possible. A randomized controlled trial is required to
confirm the safety of drainage of the pleural space for
less urgent indications.
Figure 1

Tortuous intercostal arteries.
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